Health
Cancer Leagues call for overhaul of EU drug pricing transparency rules
In a new report, ‘Behind the Price Tag’, the Association of European Cancer Leagues (ECL) has renewed calls for a major overhaul of the EU’s pharmaceutical pricing rules, arguing that the EU’s long-standing Transparency Directive no longer reflects the realities of today’s medicines market.
"The Directive has not evolved with the pharmaceutical market and risks becoming increasingly disconnected from its realities. A comprehensive revision is now essential," says ECL Executive Director, Wolfgang Fecke.
Adopted in 1989, the Transparency Directive aimed to ensure that national decisions on the pricing and reimbursement of medicines were transparent, predictable, and delivered within set timelines.
More than three decades later, however, the pharmaceutical landscape has changed dramatically. Confidential disc...

Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
Health5 days agoCounterfeit cigarettes drive illicit tobacco trade to highest level in a decade, new study claims
-
Libya5 days agoLibya’s fuel crisis offers lessons for energy security on both sides of the Mediterranean
-
Law4 days agoEU Cybersecurity Act could expose member states to costly investment treaty claims, legal opinion warns
-
Space5 days agoIn space, we can’t defend what we can’t see
